OriginalArticle EfficacyandSafetyof12-weekInterferon-basedDanoprevirRegimeninPatientswithGenotype1ChronicHepatitisC Summary: Genotype(GT)1remainsthepredominanthepatitiscvirus(HCV)GTinChinesepatients.ThisphaseIIIclinicaltrialaimedtoevaluatetheefficacyandsafetyoftheritonavir-boosteddanoprevirpluspegylated-interferonα-2aandribavirinregimenfor12weeksintreatment-na?vemainlandChinesepatientsinfectedwithHCVGT1withoutcirrhosis.Onehundredandforty-onetreatment-na?ve,non-cirrhoticHCVGT1Chinesepatients(age≥18years)wereenrolledforthissingle-arm,multicenter,phaseIIIMANASAstudy(NCT).Theprimaryend-pointwassustainedvirologicresponserateat12weeksaftertheendoftreatment.Thesecondaryend-pointsweresafetyout治疗白癜风北京医院中科治白癜风疗效更显著
